Designing an Early Access Pathway for a CNS Therapy Using Real-World and Claims Insights
Background: A mid-stage biopharma company was advancing a novel CNS therapy into late Phase II, with early clinical signals suggesting meaningful benefit for patients with progressive neurological de ...